Department of Hematology, University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC/Universidad de Sevilla, Sevilla, Spain.
Department of Hematology, University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC/Universidad de Sevilla, Sevilla, Spain.
Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):80-6. doi: 10.1016/j.clml.2013.09.014. Epub 2013 Oct 1.
Incidence, etiology, and outcome of infectious episodes in patients with myeloid neoplasms receiving azacitidine are uncertain, with no prospective data available in this group of patients. The aim of the current study was to analyze the incidence and factors related to the probability of infection in a cohort of patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) treated with azacitidine who did not receive any type of antimicrobial prophylaxis. Significantly, the group of patients who received prior intensive chemotherapy had more infectious episodes (P = 10(-4)), and particularly, invasive aspergillosis (P = .015), than patients who received frontline azacitidine. Primary antifungal prophylaxis might be recommended in MDS and AML patients receiving azacitidine as salvage therapy after intensive regimens.
阿扎胞苷治疗的骨髓增生异常综合征和急性髓系白血病患者感染事件的发生率、病因和转归尚不确定，该患者群体尚无前瞻性数据。本研究旨在分析未接受任何类型抗菌预防的阿扎胞苷治疗的骨髓增生异常综合征（MDS）和急性髓系白血病（AML）患者的感染发生率和相关因素。值得注意的是，先前接受强化化疗的患者感染发生率更高（P = 10（-4）），尤其是侵袭性曲霉菌病（P =.015），而一线阿扎胞苷治疗的患者感染发生率较低。对于接受强化治疗后作为挽救疗法的阿扎胞苷治疗的 MDS 和 AML 患者，建议进行预防性抗真菌治疗。
